Afficher la notice abrégée

Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials

dc.rights.licenseopenen_US
dc.contributor.authorWANG, Nelson
dc.contributor.authorHARRIS, Katie
dc.contributor.authorCHALMERS, John
dc.contributor.authorHARRAP, Stephen
dc.contributor.authorMANCIA, Giuseppe
dc.contributor.authorMARRE, Michel
dc.contributor.authorPOULTER, Neil
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTZOURIO, Christophe
dc.contributor.authorWILLIAMS, Bryan
dc.contributor.authorZOUNGAS, Sophia
dc.contributor.authorWOODWARD, Mark
dc.contributor.authorRODGERS, Anthony
dc.date.accessioned2021-06-30T10:17:33Z
dc.date.available2021-06-30T10:17:33Z
dc.date.issued2021-04-20
dc.identifier.issn1473-5598 (Electronic) 0263-6352 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/94939
dc.description.abstractEnOBJECTIVES: To assess the effects of combination BP lowering on cardiovascular events and mortality in the presence of aspirin and/or statin therapy in a combined analysis of the ADVANCE and PROGRESS trials. METHODS: We conducted an analysis of 14 682 participants allocated combination therapy with perindopril and indapamide or placebo followed up for a mean of 4.2 years. Participants were stratified into four groups defined by background use of medications at baseline: statin, aspirin, both or neither. Linear mixed effect models were used to assess differences in BP and Cox proportional hazard models were used to estimate the risks of major cardiovascular events, all-cause mortality and treatment discontinuation. RESULTS: At baseline, 14% of patients were on both aspirin and statin, 35% on aspirin, 9% on statins and 42% on neither aspirin/statins. Compared with placebo, combination BP therapy reduced mean SBP by 5.7 mmHg in ADVANCE and 12.1 mmHg in PROGRESS, with no difference (P > 0.447) between patients by baseline use of aspirin/statin. Combination BP therapy reduced the risk of major cardiovascular events (hazard ratio 0.78, 95% CI 0.71-0.86), with no significant difference (P = 0.600) between aspirin/statin subgroups. Rates of treatment discontinuation were similar with combination BP therapy compared with placebo (18.4 versus 18%), with no evidence of difference across the subgroups (P = 0.340). CONCLUSION: BP lowering with perindopril and indapamide reduces the risk of major cardiovascular events independent of baseline use of aspirin and/or statins.
dc.language.isoENen_US
dc.title.enCombination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/hjh.0000000000002862en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33883461en_US
bordeaux.journalJournal of Hypertensionen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamHEALTHY_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03274643
hal.version1
hal.date.transferred2021-06-30T10:17:37Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Hypertension&rft.date=2021-04-20&rft.eissn=1473-5598%20(Electronic)%200263-6352%20(Linking)&rft.issn=1473-5598%20(Electronic)%200263-6352%20(Linking)&rft.au=WANG,%20Nelson&HARRIS,%20Katie&CHALMERS,%20John&HARRAP,%20Stephen&MANCIA,%20Giuseppe&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée